Clinical-stage radiopharmaceutical company Oncoinvent ASA (Euronext Growth Oslo:ONCIN) on Monday announced updated 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis.
The trial, which closed for recruitment at the end of 2023, is now in long-term follow-up.
In the study, 10 patients received a single intraperitoneal dose of 7 MBq Radspherin. At the 12-month follow-up reported in November 2024, only one patient had experienced peritoneal recurrence.
The 18-month data showed no new recurrences, maintaining the recurrence rate at 10%. In comparable populations treated with best standard of care, approximately 40% of patients would typically have had a recurrence by this stage.
Ingenium Therapeutics' Gengleucel to enter Phase 2 trial in MRD+ AML following FDA feedback
MHRA to review monthly maintenance dosing for Leqembi in early Alzheimer's treatment
Myosin Therapeutics receives grant to advance MT-110 clinical trial in methamphetamine use disorder
CSL Vifor and Travere Therapeutics gain full EU approval for FILSPARI in IgA nephropathy
Bayer launches Phase I trial of targeted alpha therapy for advanced liver cancer
Kangpu Biopharmaceuticals' Phase IIb trial of KPG-818 approved in China
Ananda Pharma receives TGA Acknowledgement for Phase 1 clinical trial
Avacta Therapeutics reports positive Phase 1 data for lead candidate